Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
June 16, 2016

M&As this week: Trelleborg, Polpharma

Trelleborg A.B. plans to strengthen its position in the life sciences market and develop a strong platform in the sector by acquiring Speciality Silicone Fabricators, a manufacturer of high-precision medical silicone products.

PolPharma

Trelleborg A.B. plans to strengthen its position in the life sciences market and develop a strong platform in the sector by acquiring Speciality Silicone Fabricators, a manufacturer of high-precision medical silicone products.

"The acquisition is expected to be completed by the second quarter of 2016."

The acquisition is expected to be completed by the second quarter of 2016.

Polpharma S.A., a manufacturer of drug products and active pharmaceutical ingredients (API), has announced its acquirement of biopharmaceutical company EPIRUS Biopharmaceuticals.

Pursuant to the agreement, Polpharma will acquire EPIRUS Netherlands’ proprietary CHOBC cell line platform, a fully-equipped laboratory and bioreactor capabilities for the development of monoclonal antibodies and protein therapeutics, while EPIRUS Biopharma will retain exclusive rights to develop BOW080 and BOW070 for the treatment of ultra-rare blood disorder and uncommon lymphoproliferative disorder respectively.

The acquisition will enable Polpharma to expand its portfolio and EPIRUS Biopharma to pursue its reconstructing efforts of creating a separate company focused on rare disease biological products.


Image: Polpharma S.A.has announced its acquirement of EPIRUS Biopharmaceuticals. Photo: Courtesy of polpharmacommons.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU